Table 3.
Summary of a randomized clinical trial of acupuncture.
| References | Design | Sample size | Interventions | Main outcomes | Acupuncture points |
|---|---|---|---|---|---|
| [101] | RCT | 60 | Treatment group: acupuncture + TCM Control group: estradiol valerate tablets |
1. Total efficiency: treatment group—26.7% (8/30); control group—6.7% (2/30) 2. Endometrial thickness after treatment: treatment group—1.071 ± 0.144 mm; control group—1. ± 0.150 mm |
Guanyuan (RN4), Sanyinjiao (SP6) Shenshu (BL23), Zigong (EX-CA1) |
|
| |||||
| [102] | RCT | 60 | Treatment group: acupuncture + letrozole tablets Control group: letrozole tablets |
1. Total efficiency: treatment group—66.7% (20/30); control group—40.0% (12/30) 2. Endometrial thickness after treatment: treatment group—10.32 ± 1.77 mm; control group—9.31 ± 1.47 mm |
Baihui (DU20), Mingmen (DU4) Geshu (BL17), Ganshu (BL18) Shenshu (BL23), Ciliao (BL32) Guanyuan (RN4), Qihai (RN6) Dahe (KI12), Sanyinjiao (SP6) Gongsun (SP4), Daimai (GB26) |
|
| |||||
| [103] | Single-blind RCT |
60 | Treatment group: acupuncture + estradiol valerate tablets Control group: estradiol valerate tablets |
1. Total efficiency: treatment group—63.33% (19/30); control group—33.33% (10/30) 2. Endometrial thickness after treatment: treatment group—0.98 ± 0.33 mm; control group—0.68 ± 0.22 mm |
Zhongwan (RN12), Tianshu (ST25) Daimai (GB26), Guanyuan (RN4) Qihai (RN6), Zhongji (RN3) Zigong (EX-CA1), Xuehai (SP10) Zusanli (ST36), Sanyinjiao (SP6) Taichong (LV3), Mingmen (DU4) Shenshu (BL23), Ganshu (BL18) Yaoyangguan (DU3),Yaoshu (DU2) Guanyuanshu (BL26) |
|
| |||||
| [104] | RCT | 90 | Treatment group: acupuncture + TCM + aspirin enteric-coated tablets Control group: aspirin enteric-coated tablets |
Endometrial thickness after treatment: treatment group—10.59 ± 2.25 mm; control group—5.39 ± 1.00 mm | Pishu (BL20), Shenshu (BL23) Ciliao (BL32), Sanyinjiao (SP6) Shuiquan (KI5) |
|
| |||||
| [105] | RCT | 126 | Treatment group: acupuncture + moxibustion + TCM + estradiol valerate tablets + progesterone capsules Control group: estradiol valerate tablets + progesterone capsules |
1. Total efficiency: treatment group—47.6% (30/63); control group—28.6% (18/63) 2. Endometrial thickness after treatment: treatment group—7.99 ± 1.46 mm; control group—6.21 ± 1.28 mm |
Guanyuan (RN4), Taixi (KI3) Sanyinjiao (SP6), Shenshu (BL23) Mingmen (DU4), Taichong (LV3) Xingjian (LV2) |
|
| |||||
| [106] | RCT | 72 | Treatment group: acupuncture + warm group acupuncture + EA + estradiol valerate tablets Control group: estradiol valerate tablets |
1. Total efficiency: treatment group—50.0% (18/36); control group—33.3% (12/36) 2. Endometrial thickness after treatment: treatment group—9.94 ± 1.04 mm; control group—7.92 ± 1.0 mm |
Gongsun (SP4) Neiguan (PC6) |
|
| |||||
| [108] | RCT | 74 | Treatment group: Tongyuan acupuncture + estradiol valerate tablets Control group: estradiol valerate tablets |
1. Total efficiency: treatment group—37.8% (14/37); control group—16.2% (6/37) 2. Endometrial thickness after treatment: treatment group—9.61 ± 0.76 mm; control group—7.72 ± 0.51 mm |
Qiangjian (DU18), Naohu (DU17) Dazhui (DU14), Baihui (DU20) Xinshu (BL15), Geshu (BL17) Ganshu (BL18), Shenshu (BL23) Ciliao (BL32), Weizhong (BL40) Yongquan (KI1), Yintang (EX-HN3) Zhongwan (RN12), Tianshu (ST25) Guanyuan (RN4), Qihai (RN6) Luanchao (TF2), Zigong (EX-CA1) Xuehai (SP10), Zusanli (ST36) Sanyinjiao (SP6) |
|
| |||||
| [109] | Double-blind RCT | 120 | Treatment group 1: acupuncture test Treatment group 2: acupuncture control Control group: no intervention |
Total efficiency: treatment group 1—58.69% (27/46) Treatment group 2—38.29% (18/47) Control group—33.33% (9/27) |
Treatment group1: Guanyuan (RN4), Zhongji (RN3) Zigong (EX-CA1), Sanyinjiao (SP6) Guilai (ST29), Xuehai (SP10) Treatment group2: Fengshi (GB31), Yinlingquan (SP9) Waiguan (SJ5), Sidu (SJ9) |
|
| |||||
| [110] | RCT | 64 | Treatment group: EA intervention Control group: no intervention |
1. Total efficiency: treatment group—50.00% (15/30); control group—41.94% (13/31) 2. Endometrial thickness after treatment: treatment group—9.03 ± 1.68 mm; control group—9.46 ± 1.67 mm |
Baihui (DU20), Zhongwan (RN12) Guanyuan (RN4), Qihai (RN6) Zigong (EX-CA1) Fenglong (ST40) Xuehai (SP10), Sanyinjiao (SP6) Ganshu (BL18), Shenshu (BL23) |
|
| |||||
| [111] | RCT | 80 | Treatment group: EA + clomiphene citrate tablets Control group: clomiphene citrate tablets |
1. Total efficiency: treatment group—21.1% (8/38); control group—16.2% (6/37) 2. Endometrial thickness after treatment: treatment group—8.21 ± 1.08 mm; control group—6.54 ± 1.12 mm |
Qihai (RN6), Guanyuan (RN4) Dahe (KI12), Zigong (EX-CA1) Zhongji (RN3), Diji (SP8) Sanyinjiao (SP6), Shenshu (BL23) Sanjiaoshu (SP6), Ciliao (BL32) |
|
| |||||
| [112] | RCT | 80 | Treatment group: TCM + EA + aspirin enteric-coated tablets Control group: aspirin enteric-coated tablets |
1. Total efficiency: treatment group—40.0% (16/40); control group—27.5% (11/40) 2. Endometrial thickness after treatment: treatment group—8.78 ± 1.67 mm; control group—7.15 ± 1.42 mm |
Guanyuan (RN4), Zigong (EX-CA1) Zhongji (RN3), Sanyinjiao (SP6) Xuehai (SP10), Zusanli (ST36) Taixi (KI3), Zhaohai (KI6) Qihai (RN6), Yongquan (KI1) |